Maladie de Hodgkin avec atteinte médullaire
Tài liệu tham khảo
Linville, 1989, Hodgkin's disease presenting as myelofibrosis, Cancer, 15, 1720
Laplanche, 1981, L’atteinte médullaire initiale au cours de la maladie de Hodgkin, Nouv Presse Med, 10, 147
Krikorian, 1986, Hodgkin's disease presenting below the diaphragm, J Clin Oncol, 4, 1551, 10.1200/JCO.1986.4.10.1551
Duhamel, 1979, Formes médullaires massives de la maladie de Hodgkin et myélofibroses aiguës, Nouv Presse Med, 8, 1061
Fenaux, 1988, Maladie de Hodgkin révélée par une myélofibrose en apparence primitive : A propos de deux observations, Rev Med Interne, 9, 149, 10.1016/S0248-8663(88)80114-0
Talbot, 2001, 18-FDG positron imaging in clinical management of lymphoma patients, Crit Rev Oncol Hematol, 38, 193, 10.1016/S1040-8428(01)00127-5
Jerusalem, 2001, Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease, Haematologica, 86, 266
Delcambre, 2000, Clinical relevance of gallium-67 scintigraphy in lymphoma before and after therapy, Eur J Nucl Med, 27, 176, 10.1007/s002590050024
Hueltenschmidt, 2001, Whole body positron emission tomography in the treatment of Hodgkin disease, Cancer, 91, 302, 10.1002/1097-0142(20010115)91:2<302::AID-CNCR1002>3.0.CO;2-4
Bangerter, 1998, Whole body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDGPET) for accurate staging of Hodgkin's disease, Ann Oncol, 9, 1117, 10.1023/A:1008486928190
Kostacoglu, 2002, PET predicts prognosis after 1 cycle of chemotherapy in agressive lymphoma and Hodgkin's disease, J Nucl Med, 43, 1018
Jerusalem, 1999, Whole-body positron emission tomography using 18 F-Fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and pronostic value than classical computed tomography scan imaging, Blood, 94, 429, 10.1182/blood.V94.2.429
De Wit, 2001, 18FDGPET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma, Ann Oncol, 12, 29, 10.1023/A:1008357126404